companiesCompany
Shanghai Henlius Biotech
Chinese biosimilar and biologics company whose PD-1 antibody serplulimab is approved in China and Europe for small-cell lung cancer.
Serplulimab (ASTRUM-005; EU approvals 2025 for ES-SCLC, squamous NSCLC, and other indications); trastuzumab and bevacizumab biosimilars; US bridging trial for serplulimab completed enrolment.